295 related articles for article (PubMed ID: 29203139)
1. Structural Mapping of Adenosine Receptor Mutations: Ligand Binding and Signaling Mechanisms.
Jespers W; Schiedel AC; Heitman LH; Cooke RM; Kleene L; van Westen GJP; Gloriam DE; Müller CE; Sotelo E; Gutiérrez-de-Terán H
Trends Pharmacol Sci; 2018 Jan; 39(1):75-89. PubMed ID: 29203139
[TBL] [Abstract][Full Text] [Related]
2. Medicinal chemistry of adenosine, P2Y and P2X receptors.
Jacobson KA; Müller CE
Neuropharmacology; 2016 May; 104():31-49. PubMed ID: 26686393
[TBL] [Abstract][Full Text] [Related]
3. Medicinal Chemistry and Therapeutic Potential of Agonists, Antagonists and Allosteric Modulators of A1 Adenosine Receptor: Current Status and Perspectives.
Deb PK; Deka S; Borah P; Abed SN; Klotz KN
Curr Pharm Des; 2019; 25(25):2697-2715. PubMed ID: 31333094
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Novel Adenosine Receptor Antagonists through a Combined Structure- and Ligand-Based Approach Followed by Molecular Dynamics Investigation of Ligand Binding Mode.
Lagarias P; Vrontaki E; Lambrinidis G; Stamatis D; Convertino M; Ortore G; Mavromoustakos T; Klotz KN; Kolocouris A
J Chem Inf Model; 2018 Apr; 58(4):794-815. PubMed ID: 29485875
[TBL] [Abstract][Full Text] [Related]
5. G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions.
Jacobson KA; Balasubramanian R; Deflorian F; Gao ZG
Purinergic Signal; 2012 Sep; 8(3):419-36. PubMed ID: 22371149
[TBL] [Abstract][Full Text] [Related]
6. Exploring the Role of N
Petrelli R; Scortichini M; Kachler S; Boccella S; Cerchia C; Torquati I; Del Bello F; Salvemini D; Novellino E; Luongo L; Maione S; Jacobson KA; Lavecchia A; Klotz KN; Cappellacci L
J Med Chem; 2017 May; 60(10):4327-4341. PubMed ID: 28447789
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative effects of selective adenosine receptor agonists and antagonists on human lymphocytes: evidence for receptor-independent mechanisms.
Schiedel AC; Lacher SK; Linnemann C; Knolle PA; Müller CE
Purinergic Signal; 2013 Sep; 9(3):351-65. PubMed ID: 23359122
[TBL] [Abstract][Full Text] [Related]
8. Substituted 4-phenylthiazoles: Development of potent and selective A
Abdelrahman A; Yerande SG; Namasivayam V; Klapschinski TA; Alnouri MW; El-Tayeb A; Müller CE
Eur J Med Chem; 2020 Jan; 186():111879. PubMed ID: 31780082
[TBL] [Abstract][Full Text] [Related]
9. Progress in the Development of Agonists, Antagonists and Allosteric Modulators of Adenosine Receptors.
Deb PK
Curr Pharm Des; 2019; 25(25):2695-2696. PubMed ID: 31603053
[No Abstract] [Full Text] [Related]
10. Alternative quality assessment strategy to compare performances of GPCR-ligand docking protocols: the human adenosine A(2A) receptor as a case study.
Ciancetta A; Cuzzolin A; Moro S
J Chem Inf Model; 2014 Aug; 54(8):2243-54. PubMed ID: 25046649
[TBL] [Abstract][Full Text] [Related]
11. Modulation of Adenosine Receptors and Antioxidative Effect of Beer Extracts in in Vitro Models.
Alonso-Andrés P; Martín M; Albasanz JL
Nutrients; 2019 Jun; 11(6):. PubMed ID: 31163630
[TBL] [Abstract][Full Text] [Related]
12. Characterization of P1 (adenosine) purinoceptors.
Jarvis MF
Curr Protoc Pharmacol; 2013 Oct; 62():1.9.1-1.9.16. PubMed ID: 24510716
[TBL] [Abstract][Full Text] [Related]
13. Adenosine receptor desensitization and trafficking.
Mundell S; Kelly E
Biochim Biophys Acta; 2011 May; 1808(5):1319-28. PubMed ID: 20550943
[TBL] [Abstract][Full Text] [Related]
14. Characteristic molecular vibrations of adenosine receptor ligands.
Chee HK; Yang JS; Joung JG; Zhang BT; Oh SJ
FEBS Lett; 2015 Feb; 589(4):548-52. PubMed ID: 25622891
[TBL] [Abstract][Full Text] [Related]
15. A new series of 2-alkoxy(aralkoxy)-[1,2,4]triazolo[1,5-a]quinazolin-5-ones as adenosine receptor antagonists.
Al-Salahi R; Geffken D; Koellner M
Chem Pharm Bull (Tokyo); 2011; 59(6):730-3. PubMed ID: 21628909
[TBL] [Abstract][Full Text] [Related]
16. The Influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl Moiety on the Adenosine Receptors Affinity Profile of Pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c]Pyrimidine Derivatives.
Federico S; Redenti S; Sturlese M; Ciancetta A; Kachler S; Klotz KN; Cacciari B; Moro S; Spalluto G
PLoS One; 2015; 10(12):e0143504. PubMed ID: 26625265
[TBL] [Abstract][Full Text] [Related]
17. Fluorescent ligands for adenosine receptors.
Kozma E; Jayasekara PS; Squarcialupi L; Paoletta S; Moro S; Federico S; Spalluto G; Jacobson KA
Bioorg Med Chem Lett; 2013 Jan; 23(1):26-36. PubMed ID: 23200243
[TBL] [Abstract][Full Text] [Related]
18. Expeditious synthesis and biological evaluation of new C-6 1,2,3-triazole adenosine derivatives A1 receptor antagonists or agonists.
Mathew SC; By Y; Berthault A; Virolleaud MA; Carrega L; Chouraqui G; Commeiras L; Condo J; Attolini M; Gaudel-Siri A; Ruf J; Rodriguez J; Parrain JL; Guieu R
Org Biomol Chem; 2010 Sep; 8(17):3874-81. PubMed ID: 20617271
[TBL] [Abstract][Full Text] [Related]
19. Contractile effects and receptor analysis of adenosine-receptors in human detrusor muscle from stable and neuropathic bladders.
Pakzad M; Ikeda Y; McCarthy C; Kitney DG; Jabr RI; Fry CH
Naunyn Schmiedebergs Arch Pharmacol; 2016 Aug; 389(8):921-9. PubMed ID: 27185496
[TBL] [Abstract][Full Text] [Related]
20. Modulation of G protein-coupled adenosine receptors by strategically functionalized agonists and antagonists immobilized on gold nanoparticles.
Jayasekara PS; Phan K; Tosh DK; Kumar TS; Moss SM; Zhang G; Barchi JJ; Gao ZG; Jacobson KA
Purinergic Signal; 2013 Jun; 9(2):183-98. PubMed ID: 23179047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
